Search results
Results from the WOW.Com Content Network
Ranitidine, previously sold under the brand name Zantac [a] among others, is a medication used to decrease stomach acid production. [12] It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [12] It can be given by mouth, injection into a muscle, or injection into a vein.
Ranitidine bismuth citrate 400 mg 2 times a day, metronidazole 500 mg 3 times a day, tetracycline 500 mg 4 times a day. Scheme 4. 2 times a day - ranitidine bismuth citrate 400 mg, tinidazole 500 mg, amoxicillin 1 g. Within 14 days - 2 drugs: Scheme 5. Ranitidine bismuth citrate 400 mg 2 times a day and clarithromycin 500 mg 2 or 3 times a day.
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
Ranitidine, a heartburn medicine sold under the brand name Zantac among others, was pulled from shelves in 2019, [1] following disclosure [2] of potential carcinogenic effects, [3] [4] which its manufacturers were accused of "engaging in a decades-long scheme to conceal." [5]
Zantac can refer to either of two different H 2 antagonists used to reduce gastric acid secretion: ... This page was last edited on 20 December 2023, at 21:42 (UTC).
Nizatidine was developed by Eli Lilly, and was first marketed in 1988. [3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine.
Zantac (ranitidine) 300 mg tabletsRanitidine was first prepared as AH19065 by John Bradshaw in the summer of YEAR in the War research laboratories of Allen & Hanburys Ltd, part of the Glaxo organization. 192.139.126.234 16:02, 6 September 2013 (UTC)
Molecular structure of ranitidine. In 1976, a predecessor of GlaxoSmithKline Inc. ("GSK") discovered the drug ranitidine, which was approved for sale in Canada in 1981 and marketed as Zantac. Ranitidine's primary manufacture was conducted by related companies located in the United Kingdom and Singapore, and it was subsequently sold to Adechsa ...